Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of STL303 in adults with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. GA leads to gradual cell death in the back of the eye, causing blurry or missing central vision spots. This randomized, double-masked, multi-center study aims to find the best dose of STL303 and assess its impact on this eye condition. Participants will be randomly assigned to receive either one of two doses of oral STL303 or a placebo. The study compares these groups to understand how STL303 affects the rate of vision loss and other eye health measures. The treatment period lasts up to 104 weeks, with evaluations continuing through week 108 to monitor safety and disease progression. During the study, participants will undergo regular eye exams, including imaging scans and vision tests, to track changes in their condition. Researchers will measure the reduction in the area of eye damage, retinal sensitivity, and vision-related quality of life. Blood samples will be collected at scheduled visits to analyze how the drug is processed in the body. Participants will also record daily medication use and attend frequent study visits for assessments and safety monitoring. The total trial participation may last several years until study completion in 2029.
Actively Recruiting
Atrial fibrillation is the most common heart rhythm problem worldwide and increases the risk of heart failure, stroke, and death. Researchers expect its prevalence to rise, especially in people over 65 years old, with about one in three developing atrial fibrillation. Electrocardioversion is a procedure that restores normal heart rhythm but often results in the arrhythmia returning within a short time. This trial aims to study whether inflammation plays a role in this recurrence and if treating it can reduce the return of atrial fibrillation after electrocardioversion. The trial compares two groups one receives a daily oral dose of 0.5 mg Colchicine for three months, taken in the morning without a loading dose, alongside their usual treatments. The other group receives a matched placebo. This is a randomized, triple-blind Phase 3 study evaluating the effect of low-dose Colchicine on preventing atrial fibrillation recurrence after electrocardioversion. Participants will be monitored for recurrence of atrial fibrillation over six months following electrocardioversion. Researchers will assess the number of arrhythmia recurrences at one, three, and six months, the time to any repeat electrocardioversion, use of antiarrhythmic drugs, and hospitalizations. Safety and overall wellbeing will also be followed during this period, with the main outcome focused on arrhythmia recurrence within six months.
Actively Recruiting
Researchers are assessing the long-term safety and tolerability of the Port Delivery System with ranibizumab PDS in people with neovascular age-related macular degeneration nAMD who have completed previous related studies or certain visits within those studies. The trial includes two sub-studies to evaluate specific aspects one tests the effectiveness of transscleral photocoagulation to reduce vitreous hemorrhages after PDS implantation, and the other assesses the safety of re-implantation with an updated PDS device. Participants receive the PDS implant with ranibizumab at a concentration of 100 mgmL, administered through refill-exchange procedures at set intervals varying by previous study involvement, typically every 24 weeks with some switching to every 12 weeks later in the trial. The sub-studies involve additional treatments such as laser therapy or re-implantation and follow-up for up to 72 weeks. Treatment schedules and monitoring differ depending on enrollment cohorts and prior participation. Throughout the study, participants undergo regular assessments including eye exams, imaging, and monitoring for adverse events related to the PDS implant and ranibizumab treatment. The study tracks vision changes, ocular health, device safety, and any complications over periods up to 240 weeks or longer if regulatory approval is pending. Participants adherence to visit schedules and safety measures are closely observed as part of the trials long-term evaluation.
Actively Recruiting
Researchers are conducting a prospective, multinational, multicenter observational study to predict the progression from early and intermediate age-related macular degeneration AMD with functional vision to advanced AMD that causes irreversible vision loss over two years. The study aims to identify and measure specific changes in the retina related to disease progression, assess individual risk of advancing to severe AMD using imaging, clarify the sequence of events leading to advanced AMD, and improve AMD classification by using artificial intelligence alongside traditional methods. Participants will be monitored for 24 months with visits every six months. During these visits, researchers will perform non-invasive imaging tests including scanning laser fundus photography, color fundus photography, optical coherence tomography, and optical coherence tomography angiography. Participants will also provide medical history and complete standard eye exams and questionnaires about their vision. No treatments will be given as part of the study since no approved treatment is currently available in Europe, but if treatments become approved, patients may receive them as part of their usual care outside the study. Throughout the study, investigators will track retinal changes and disease progression using imaging and questionnaires. The main outcome is to characterize retinal alterations to identify patients at risk of developing advanced AMD. Secondary outcomes include identifying biomarkers of disease progression and evaluating the use of AI to monitor AMD. Safety and standard care will be maintained, and participants will be followed closely to understand AMD progression over time.
Actively Recruiting
Researchers are conducting a prospective, multinational, multicenter observational study to assess and predict how non-foveal, non-vision compromising atrophic age-related macular degeneration AMD progresses in individual patients over two years. The study aims to measure the rate of progression, identify changes in the retina related to the disease, and evaluate the use of approved artificial intelligence AI algorithms to monitor AMD progression. This research is important as no treatment is currently approved in Europe for this condition. Participants will be followed for 24 months with check-ins every 6 months. During these visits, routine eye imaging tests will be performed, including Scanning Laser Fundus Photography, Color Fundus Photography, Optical Coherence Tomography, and Optical Coherence Tomography Angiography. Patients medical histories will be reviewed, and standard eye exams plus questionnaires about visual function will be completed. No specific treatment will be given as part of the study however, if a treatment becomes approved in the EU during the study, patients may receive it following standard care outside the study. Participants will undergo regular assessments focusing on imaging to characterize and quantify retinal changes linked to geographic atrophy progression. Researchers will use these images and AI tools to identify patients at risk for faster disease progression. Safety monitoring will continue throughout the 2-year period, and the study will collect data on disease progression biomarkers and AI monitoring effectiveness. This observational approach will help improve understanding of AMD progression without altering patient care during the study.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called ONL1204 in people aged 55 and older who have geographic atrophy GA related to age-related macular degeneration AMD. GA associated with AMD is a leading cause of vision loss and blindness globally, linked to aging and other risk factors. This phase 2 study aims to understand how different doses and treatment schedules of ONL1204 affect this condition. Participants will receive one of several treatments ONL1204 injections at two dose levels 100 or 200 micrograms every 12 weeks, ONL1204 200 micrograms every 24 weeks, sham injections every 12 or 24 weeks, or monthly injections of avacincaptad pegol. All injections are given into the eye intravitreal. This randomized, double-masked trial compares these different groups over a period of 48 weeks. During the study, participants will have regular visits for eye exams, imaging, and vision tests to monitor their condition and treatment effects. Researchers will track safety and efficacy outcomes throughout the 48 weeks. Participants must meet specific vision and eye health criteria to join, and safety monitoring will continue throughout the treatment period to ensure participant well-being.